Arcus Biosciences, Inc. (NYSE:RCUS) · earnings preview
Quarter
Q3
EPS estimate to actual
-$0.88
Revenue estimate to actual
$12.2M
At a glance
Key takeaways
01Arcus Biosciences will report Q3 2026 earnings on October 27, 2026 after market close with expected EPS of -$0.88, significantly worse than the $0.00 from Q3 2025.
02Revenue is projected at $12.2M, showing growth compared to the prior year quarter despite ongoing losses.
03The stock trades at $17.66 with a $2.7B market capitalization as of the article date.
04Recent earnings history shows mixed performance: Q2 beat estimates by 15.3%, but Q1 missed by 20%, indicating volatility in results versus analyst expectations.
05Investors should evaluate revenue growth, margin trends, and forward guidance alongside the headline EPS figure to assess business direction.
Earnings Results
Arcus Biosciences, Inc. (NYSE:RCUS) is scheduled to report its Q3 earnings results on October 27, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-0.88, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $12.2M, up from a year ago.
Company Overview
The stock currently trades at $17.66 with a market capitalization of $2.7B.
Ahead of Arcus Biosciences, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Arcus Biosciences, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.